Expedited Registration Pathways in Thailand: Abridged, Reliance and MDA Pilot

Note. This is a dynamic page: the list of reference authorities and the membership of reliance programmes are adjusted by Thai FDA announcements, so the current published lists prevail.

1. Key takeaways

Thailand operates three accelerated channels, available for Classes 2-4, and their value differs sharply depending on which foreign approval an applicant already holds. The essentials are set out below.

• Abridged (simplified assessment): available where the device has been approved by a designated reference authority for at least 1 year. It waives certain documents (the verification and validation summary, risk analysis and disposal documents) and avoids expert review.
• Reliance (Singapore HSA): available where the device is already approved by the Singapore HSA and stands validly on the Singapore registration listing. Review shortens from 150 working days to 60 working days, and the expert review is waived, saving about 53,000 baht.
• MDA pilot (Malaysia reliance): available where the device is already approved by the Malaysian MDA. Under this bilateral reliance programme there is no holding-period requirement.
• Reference authorities recognised under the Thai FDA announcement of June 4, 2024 (B.E. 2567): the US FDA, EU Notified Bodies, Health Canada, the Australian TGA and the Japanese MHLW (approval held for at least 1 year); WHO Prequalification (IVDs only, likewise 1 year); and the Singapore HSA and Malaysian MDA under the bilateral reliance programmes with no holding period.
• The Malaysian MDA was added by an announcement signed on October 6, 2026 — the most significant channel expansion of 2026.
• Abridged waives the verification and validation summary and risk analysis, but requires in exchange: declarations of intended use and indications, a Market History Declaration, a Safety Declaration, and evidence of the reference authority approval.
• Certificates obtained through Reliance or the abridged route must be supplemented with a complete dossier if transferred later — a cost to weigh at pathway selection, not at transfer time.

2. Legal basis

The reference authority framework derives from the Thai FDA reliance announcement of June 4, 2024 (B.E. 2567), and the accession of the Malaysian MDA comes from the announcement signed on October 6, 2026. The document obligations for each route follow the Class 2-4 document matrix published on the Thai FDA website, which compares the Full, Abridged and Reliance with HSA columns. The HSA Reliance conditions are: the CSDT submitted to the Thai FDA must be identical to the version submitted to the HSA, including subsequent change notifications; the Singapore registrant must sign the HSA-Thai FDA reliance consent letter authorising the HSA to share its assessment report; the submission must include the HSA-approved change notifications, the regulatory reliance participation letter, the HSA approval evidence and the consent letter; and the device must be in valid status on the Singapore registration listing. The summary of the three routes is as follows.

3. Expert insights

The abridged route should be understood as an exchange rather than a discount. Relative to the Full route it waives the verification and validation summary and the risk analysis, but it adds requirements: declarations covering intended use and indications, a Market History Declaration, a Safety Declaration, and proof of the reference authority approval. These declarations are the consideration paid for the exemption — a documented market history and safety record are traded for relief from parts of the technical file. Applicants who can substantiate that history cleanly benefit enormously; applicants who cannot should stay on the Full route rather than build the abridged file on shaky foundations.

Reliance on the HSA is frequently misdescribed as submitting less. The opposite is closer to the truth: it requires more evidence of the dependency itself. Four conditions apply: the CSDT submitted to the Thai FDA must match the version submitted to the HSA, including later change notifications; the Singapore registrant must sign the HSA-Thai FDA reliance consent letter authorising the HSA to share its assessment report; the HSA-approved change notifications, the regulatory reliance participation letter, the HSA approval evidence and the consent letter must be submitted; and the device must remain in valid status on the Singapore registration listing. The reward for meeting these conditions is the largest single time saving in the Thai system: review reduced from 150 working days to 60 working days, with the expert review waived and roughly 53,000 baht saved.

One further consequence deserves early attention: certificates obtained through Reliance or the simplified route must be supplemented with a complete dossier when they are later transferred. Time saved at registration can therefore be repaid at transfer, and the possibility of changing licence holders should be considered when the pathway is chosen, not afterwards.

4. Practical recommendations

• Make the existence of a reliance-able foreign approval the first question of pathway design, before any dossier writing begins.
• For manufacturers already approved in Singapore or Malaysia, use the bilateral reliance programmes: they carry no holding-period requirement and can be used immediately.
• For manufacturers holding reference-authority approvals (US FDA, EU notified body, TGA, Health Canada, Japanese MHLW, or WHO Prequalification for IVDs) valid for at least 1 year, use the Abridged route.
• Remember that the 1-year holding period is a hard condition: a US clearance obtained last month cannot yet be used, but a Singapore or Malaysian approval can be used immediately.
• If a future change of licence holder is plausible, weigh the transfer supplementation obligation before committing to Reliance or Abridged, and consider building the Full dossier base in parallel.
• Keep the CSDT submitted to the Thai FDA synchronised with the HSA version, including every change notification, to preserve Reliance validity.

5. Verification checklist

• □ Thai FDA reliance announcement (June 4, 2024, B.E. 2567) and its list of reference authorities
• □ Announcement on the Malaysian MDA joining the reliance programme (signed October 6, 2026)
• □ Thai FDA website Class 2-4 document matrix (Full / Abridged / Reliance with HSA, three-column comparison)
• □ HSA Reliance terms (150 to 60 working days, expert review waived, saving about 53,000 baht)
• □ Abridged exemptions (verification and validation summary, risk analysis) and added declarations (intended use, market history, safety)
• □ Rule that certificates from simplified or reliance routes must be supplemented with a complete dossier upon transfer

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Thailand. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the Thai FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com